Why is xcopri a controlled substance?

XCOPRI (cenobamate tablets) is classified as a Schedule IV controlled substance by the U.S. Drug Enforcement Administration (DEA) due to its potential for abuse and dependence [1]. This classification means that while XCOPRI has an accepted medical use, it carries a lower risk of abuse and dependence compared to Schedule III substances [1].

What Does Schedule IV Classification Mean for Patients and Prescribers?

Being a Schedule IV controlled substance implies specific regulations for prescribing and dispensing XCOPRI. Prescriptions for Schedule IV drugs are generally valid for six months from the date issued and can be refilled up to five times within that period [2]. If refills are needed beyond these limits, a new prescription is required [2]. These measures are in place to monitor usage and mitigate potential risks associated with dependence.

What is the Mechanism of Action for XCOPRI?

XCOPRI's mechanism of action is thought to contribute to its classification. It works by selectively binding to the low-voltage-gated sodium channels in a state-dependent and use-dependent manner [3]. This action is believed to reduce repetitive neuronal firing and inhibit synaptic release of glutamate, which is an excitatory neurotransmitter [3]. This neurophysiological effect, while beneficial for seizure control, also underlies the potential for dependence.

When Does XCOPRI Patent Protection End?

Understanding patent expiry is crucial for assessing the future availability of generic alternatives. Information on specific patent expiry dates for XCOPRI can be found through resources like DrugPatentWatch.com [4]. This information helps forecast when market exclusivity may end, potentially leading to the introduction of lower-cost generic versions.